HR and breast carcinoma: To evaluate the impact of continued CDK4/6i treatment in drug-resistant settings, we employed HR+/HER2− breast cancer cell lines (MCF-7, T47D, and CAMA-1) and a triple-negative breast cancer cell line (MDA-MB-231), all of which have an intact Rb/E2F pathway.